Specific adverse events predict survival rates in a Chinese population diagnosed with hepatocellular carcinoma and treated with sorafenib.
Teng-Yu LeeTeng-Yu LeeSheng-Shun YangYen-Chun PengHong-Zen YehChi-Sen ChangPublished in: JGH open : an open access journal of gastroenterology and hepatology (2018)
The appearance of sorafenib AEs, including HFSR, HTN, and diarrhea, can predict a positive therapy efficacy to HCC.